2.5
Graves hastalığı, hipertiroidize veya tiroid bezinin aşırı aktivitesine neden olan otoimmün bir hastalıktır. Tiroid uyarıcı immünoglobulinler (TSI) ad…
Graves hastalığı, otoimmün bir durumdur ve hipertiroidizmin başlıca nedenidir. Bağışıklık sistemi, tiroid bezini anormal şekilde aktive eden otoantikor türü olan tiroid uyarın immünoglobulinler ürettiğinde gelişir.
Bu antikorlar tiroid bezindeki TSH reseptörlerine bağlanır ve bu da tiroid hormonlarının aşırı üretimine yol açar.
Bu, vücudun metabolik hızını artırır ve kalp atış hızı ile sıcaklık düzenlemesi gibi fonksiyonları etkiler.
Graves hastalığı, genetik bir yatkınlıkla—özellikle HLA-DR3 ve HLA-B8 varyantlarıyla—ve sigara içme ve stres gibi çevresel tetikleyicilerle bağlantılıdır.
Bu spesifik HLA tipleri, tiroid proteinlerini değiştirilmiş şekilde sunabilir, bu da otoreaktif T hücrelerinin aktive olma olasılığını artırır ve dolayısıyla Graves hastalığı gelişme riskini artırır.
Klinik olarak, kilo kaybı, ısı intoleransı, çarpıntı ve adet düzensizlikleri gibi hipertiroidizm belirtileriyle birlikte ortaya çıkar.
Genellikle bir guatr veya büyümüş tiroid bezi bulunur. Ekzoftalmos ve periorbital ödem ile karakterize edilen oftalmopati, ayırt edici bir özelliktir.
View the full transcript and gain access to JoVE Core videos
Q1: What causes Graves' disease to develop?
Graves' disease develops when the immune system produces thyroid-stimulating immunoglobulins, autoantibodies that abnormally activate the thyroid gland. These antibodies bind to TSH receptors on thyroid cells, triggering excessive hormone production. The condition combines genetic predisposition—particularly HLA-DR3 and HLA-B8 variants—with environmental triggers such as smoking, stress, and viral infections.
Q2: How do thyroid-stimulating immunoglobulins affect the body?
Thyroid-stimulating immunoglobulins bind to TSH receptors on the thyroid gland, leading to excessive production of thyroid hormones. This increases the body's metabolic rate and disrupts functions such as heart rate and temperature regulation, creating a hypermetabolic state characteristic of hyperthyroidism.
Q3: What are the main clinical symptoms of Graves' disease?
Graves' disease presents with weight loss, heat intolerance, palpitations, tachycardia, tremors, anxiety, and menstrual irregularities. A diffuse goiter typically causes visible neck swelling. Ophthalmopathy, a distinctive autoimmune feature, includes exophthalmos, eye dryness, redness, and in severe cases, visual disturbances or pain.
Q4: What role do genetic factors play in Graves' disease?
Graves' disease has a strong genetic component, with increased prevalence in individuals carrying HLA-DR3 and HLA-B8 alleles. These specific HLA types present thyroid proteins in an altered manner, increasing the likelihood of activating autoreactive T cells. Family clustering and higher concordance in monozygotic twins demonstrate the hereditary nature of susceptibility.
Q5: How is Graves' disease related to other autoimmune disorders?
Graves' disease is associated with other autoimmune disorders such as type 1 diabetes and pernicious anemia, indicating underlying immune dysfunction. This clustering suggests shared genetic predisposition and common mechanisms of immune dysregulation that increase risk for multiple autoimmune conditions simultaneously.
Q6: What is ophthalmopathy and how does it manifest in Graves' disease?
Ophthalmopathy is a distinctive autoimmune feature of Graves' disease characterized by exophthalmos, or forward bulging of the eyes, along with periorbital edema. Patients experience eye dryness, redness, tearing, and diplopia. In severe cases, visual disturbances or pain may occur, making ophthalmopathy a defining clinical marker.
Q7: What environmental factors can trigger or worsen Graves' disease?
Environmental triggers include smoking, which significantly aggravates ophthalmopathy, viral infections through molecular mimicry mechanisms, emotional stress, and excess iodine intake. These factors interact with genetic predisposition to disrupt immune regulation, leading to B-cell production of thyroid-stimulating immunoglobulins and disease initiation or progression.